There are 2949 resources available
IO combinations early or intermediate-stage HCC: Current evidence and ongoing trials
Presenter: Ghassan Abou-Alfa
Session: AstraZeneca - Current status and future directions for immunotherapy in hepatocellular carcinoma
Resources:
Webcast
Putting it all together: Case discussions
Presenter: Bruno Sangro
Session: AstraZeneca - Current status and future directions for immunotherapy in hepatocellular carcinoma
Resources:
Webcast
The payer perspective: Utilising RWD to determine the value of drugs
Presenter: Oriol Solà-Morales
Session: Pfizer Oncology - RWE and me: Multidisciplinary views on real-world evidence (RWE) in oncology
Resources:
Webcast
Panel discussion
Presenter: George Demetri, Jorge Camarero, Oriol Solà-Morales, Renate Haidinger
Session: Pfizer Oncology - RWE and me: Multidisciplinary views on real-world evidence (RWE) in oncology
Resources:
Webcast
Welcome and Introduction
Presenter: James Larkin
Session: Bristol Myers Squibb - Harnessing the Potential of the Immune System: Clinical Insights From Utilizing CTLA-4 Within a Dual I-O Approach in aRCC
Resources:
Webcast
Deepening Our Understanding of Dual Checkpoint Inhibition
Presenter: Michael Atkins
Session: Bristol Myers Squibb - Harnessing the Potential of the Immune System: Clinical Insights From Utilizing CTLA-4 Within a Dual I-O Approach in aRCC
Resources:
Webcast
Clinical Lessons Learned From the Use of Dual I-O Therapy
Presenter: James Larkin
Session: Bristol Myers Squibb - Harnessing the Potential of the Immune System: Clinical Insights From Utilizing CTLA-4 Within a Dual I-O Approach in aRCC
Resources:
Webcast
Exploring Treatment Advancements in aRCC with CTLA-4 and PD-1 Inhibition
Presenter: Nizar Tannir
Session: Bristol Myers Squibb - Harnessing the Potential of the Immune System: Clinical Insights From Utilizing CTLA-4 Within a Dual I-O Approach in aRCC
Resources:
Webcast
Summary and Close
Presenter: James Larkin
Session: Bristol Myers Squibb - Harnessing the Potential of the Immune System: Clinical Insights From Utilizing CTLA-4 Within a Dual I-O Approach in aRCC
Resources:
Webcast
Welcome and introduction
Presenter: Rosario Garcia Campelo
Session: Pfizer Oncology - Treatment considerations in biomarker-driven NSCLC: Diagnostics and sequencing
Resources:
Webcast